What's Up Collector Prévention
•Télécharger en tant que PPT, PDF•
1 j'aime•533 vues
Par F. DIevart
![Prévention du diabète ,[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommandé
Recommandé
Contenu connexe
En vedette
En vedette (20)
Similaire à What's Up Collector Prévention
Similaire à What's Up Collector Prévention (20)
Dernier
Dernier (7)
What's Up Collector Prévention
- 1. ACC 2010, ATLANTA L’actualité 2010 en cardiologie Les grandes études de prévention DIEVART François Clinique Villette, Dunkerque
- 7. Natéglinide : événements CV Holman RR et al, N Engl J Med, 2010
- 12. Réduction de PA sous valsartan McMurray JJ et al, N Engl J Med, 2010
- 13. Incidence du DNID McMurray JJ et al, N Engl J Med, 2010
- 14. Événements CV McMurray JJ et al, N Engl J Med, 2010
- 18. Baseline Patient Characteristics Holman RR et al, N Engl J Med, 2010
- 19. Baseline Patient Characteristics (continued) Holman RR et al, N Engl J Med, 2010
- 20. Concomitant Medications Holman RR et al, N Engl J Med, 2010
- 21. Concomitant Medications (continued) Holman RR et al, N Engl J Med, 2010
- 22. NateglinideDecreased FPG; Increased 2Hr PG Holman RR et al, N Engl J Med, 2010
- 23. Weight and WaistCircumference IncreasewithNateglinide Holman RR et al, N Engl J Med, 2010
- 24. Baseline Patient Characteristics McMurray JJ et al, N Engl J Med, 2010
- 25. Baseline Patient Characteristics (continued) McMurray JJ et al, N Engl J Med, 2010
- 26. Concomitant Medications McMurray JJ et al, N Engl J Med, 2010
- 28. ValsartanSignificantlyReduced MeanSitting BP McMurray JJ et al, N Engl J Med, 2010
- 29. ValsartanReducedFasting and 2Hr Glucose McMurray JJ et al, N Engl J Med, 2010
- 30. Incidence of Diabetes McMurray JJ et al, N Engl J Med, 2010
- 31. Extended and Core CV Outcomes McMurray JJ et al, N Engl J Med, 2010
- 32. ExploratoryOutcomes : CV & Total Mortality McMurray JJ et al, N Engl J Med, 2010
- 33. Adverse Events of Interest * MedDRA preferred terms include: hypotension, dizziness (including dizziness exertional, dizziness postural), syncope, presyncope and shock (not otherwise specified) McMurray JJ et al, N Engl J Med, 2010
- 34. ACC 2010, ATLANTA L’actualité 2010 en cardiologie Les grandes études de prévention DIEVART François Clinique Villette, Dunkerque
- 37. Étude(s) ACCORD
- 39. ACCORD lipides effets sur les lipides plasmatiques
- 41. Biologie Section 15 : Results – SerumCreatinineLevels Over Time SinceRandomization Mean (+ confidence interval ) serumlevels of creatinine (mg/dl) atbaseline and annualythereafter in the fenofibrate (red) and placebo (blue) groups
- 42. Critère primaire dans les sous-groupes
- 43. Critère primaire dans les sous-groupes
- 47. ACCORD Lipides Diapositives supplémentaires
- 49. Critère primaire
- 51. AHA 2009, ORLANDO L’actualité 2010 en cardiologie Les grandes études de prévention DIEVART François Clinique Villette, Dunkerque
- 60. Caractéristiques à l’inclusion Caractéristiqueséquilibrées entre les 2 groupes .
- 66. Résultat final (JACC 2010) Table 3 : Change From Baseline CIMT by Treatment Group for CompletingSubjects And for All SubjectsWith the Last Observation CarriedForward
- 67. Résultat final (JACC 2010) Figure 1 : Relationship BetweenQuarties of Cumulative Drug Exposure to Ezetimibe And Niacin and Change in CIMT Cumulative drugexposurewascalculated as the product of meanstudydrugadherence, close and time in the study . The relationshipbetween ( lowest, quartile 1, to highest, quartile 4) and change in meancarotidintima-mediathickness (CIMT) for all subjectsusing the method of last observation carried. Forwardisshown. The relationshipbetween quartiles of cumulative drugexposure and charge in CIMT isshownseparately for ezetimibe (blue line) (analysis of variance (ANOVA) p = 0.05) and niacin (red line) (ANOVA p = 0.23)
- 71. AHA 2009, CHICAGO L’actualité 2010 en cardiologie Les grandes études de prévention DIEVART François Clinique Villette, Dunkerque
- 76. HDL : Reverse cholesterol transport
- 77. Reverse cholesterol transport and HDL metabolism CE= cholesterol ester; FC= free cholesterol; A-1= apolipoproteinA-1; ABC1= ATP-binding cassettte protein-1; LCAT= Lecithin:cholesterol acyl transeferase; SR-B1=scavenger receptor class B1
- 79. HDL LDL / VLDL Liver Bile CE LDL-R FC FC LCAT CETP CE SR-B1 Free Cholesterol (FC) in Extrahepatic tissues CETP La Cholesteryl ester transfer protein (CETP) est une protéine plasmatique qui catalyse le transfert du cholestérol estérifié depuis les HDL jusqu’au apo-B (VLLD et LDL) en échange des triglycérides. X inhibition
- 81. Étude ILLUMINATE: pronostic à long termes de coronariens ou équivalents coronariens
- 84. DEFINE Safety of Anacetrapib in Patients with or at Risk for Coronary Heart Disease Christopher P. Cannon, MD, Sukrut Shah, PhD, RPh, Hayes M. Dansky, MD, Michael Davidson, MD, Eliot A. Brinton, MD, Antonio M. Gotto, Jr., MD, DPhil, Michael Stepanavage, MS, Sherry Xueyu Liu, MS, Patrice Gibbons, MS, Tanya B. Ashraf, BA, Jennifer Zafarino, MS, Yale Mitchel, MD, Philip Barter, MD, PhD, for the DEFINE Investigators D etermining the EF ficacy and Tolerability of CETP IN hibitionwithAnac E trapib
- 86. Protocole de l’étude DEFINE
- 87. Effets sur le LDL-C et le HDL-C
- 89. L’Anacetrapib ne modifie pas la pression artérielle
- 90. L’Anacetrapib ne modifie pas les paramètres surveillés pour évaluer sa sécurité d’emploi
- 91. Événements CV et décès ** Post hoc analysis
- 94. CONCLUSION Cannon CP et al. N Engl J Med 2010;363 (19) online 11/17/2010
- 98. ACC 2010, ATLANTA L’actualité 2010 en cardiologie Les grandes études de prévention DIEVART François Clinique Villette, Dunkerque
- 102. Étude(s) ACCORD
- 103. Étude ACCORD PA : résultats sur la PAS (moyenne + IC 95%)
- 105. ACCORD PA : Paramètres évalués à la dernière visite
- 106. ACCORD PA : Résultats sur les critères primaires et secondaires Also examined Fatal/Nonfatal HF (HR=0.94, p=0.67), a composite of fatal coronary events, nonfatal MI and unstable angina (HR=0.94, p=0.50) and a composite of the primary outcome, revascularization and unstable angina (HR=0.95, p=0.40)
- 111. ACCORD PA en résumé Diapositives supplémentaires
- 114. ACCORD PA : Caractéristiques à l’inclusion * Median Value
- 115. Traitements prescrits (à la visite du 12 ème mois)
- 116. PAD (moyenne + IC95%)
Notes de l'éditeur
- Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the transfer of CE from HDL to apoB-containing lipoproteins (VLDL and LDL-C)in exchange for triglycerides that are transferred in the reverse direction. CETP inhibitors increase HDL-C and some also lower LDL-C, and therefore have the potential to reduce coronary events. HDL picks up free cholesterol (FC) from extrahepatic tissues. HDL FC is subsequently esterified by LCAT to form cholesteryl esters (CE) The HDL CE may then be delivered to the liver by either of two pathways: 1. A direct pathway following binding of HDL to hepatic SR-B1 2. An indirect pathway involving the CETP-mediated transfer of CE from HDL to VLDL and LDL with subsequent delivery to the liver following binding of LDL to the LDL receptor." After click: Inhibition of CETP prevents the transfer of CE from HDL to the VLDL/LDL fractions and results in an increase in concentration of HDL-C and a decrease in the cholesterol content of the VLDL/LDL.
- ILLUMINATE is a multicenter, double-blind, parallel-group, clinical end point trial that is being conducted at 250 sites in 7 countries. Approximately 13,000 subjects with CHD or CHD risk equivalent will be randomized to treatment without regard to their baseline HDL-C levels. The primary end point is a composite of CHD death, nonfatal MI, or stroke. The study population includes men and women, 45 to 75 years of age, who have a prior history of CHD or a CHD risk equivalent and who are eligible for statin treatment. Baseline HDL-C level is not a feature of the inclusion or exclusion criteria. Subjects initially enter an atorvastatin run-in period during which atorvastatin treatment is initiated. Subjects previously treated with other statins are switched to an equivalent dose of atorvastatin. The atorvastatin dose is then titrated to a target LDL-C level of <100 mg/dL (2.6 mmol/L). Following attainment of the LDL-C goal, patients are randomized to either torcetrapib/atorvastatin or atorvastatin alone. In both treatment arms, the dose of atorvastatin is that established during the atorvastatin run-in phase. Follow-up is driven by end points (984 events) and estimated to last approximately 4.5 years. The primary end point is a composite of CHD death, nonfatal MI, or stroke.
- No p-value available for aldo